Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection

Two human monoclonal antibodies (MAbs) (2F5 and 4E10) against the human immunodeficiency virus type 1 (HIV-1) envelope g41 cluster II membrane proximal external region (MPER) broadly neutralize HIV-1 primary isolates. However, these antibody specificities are rare, are not induced by Env immunizatio...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of virology Vol. 82; no. 1; p. 115
Main Authors:	Alam, S Munir, Scearce, Richard M, Parks, Robert J, Plonk, Kelly, Plonk, Steven G, Sutherland, Laura L, Gorny, Miroslaw K, Zolla-Pazner, Susan, Vanleeuwen, Stacie, Moody, M Anthony, Xia, Shi-Mao, Montefiori, David C, Tomaras, Georgia D, Weinhold, Kent J, Karim, Salim Abdool, Hicks, Charles B, Liao, Hua-Xin, Robinson, James, Shaw, George M, Haynes, Barton F
Format:	Journal Article
Language:	English
Published:	United States 01.01.2008
Subjects:	Animals Antibodies, Monoclonal - immunology Antibodies, Monoclonal - isolation & purification Cross Reactions Epitopes - immunology HIV Antibodies - blood HIV Antibodies - immunology HIV Antibodies - metabolism HIV Envelope Protein gp41 - immunology HIV Infections - immunology HIV-1 - immunology Humans Kinetics Lipids - immunology Mice Neutralization Tests Protein Binding
ISSN:	1098-5514, 1098-5514
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Two human monoclonal antibodies (MAbs) (2F5 and 4E10) against the human immunodeficiency virus type 1 (HIV-1) envelope g41 cluster II membrane proximal external region (MPER) broadly neutralize HIV-1 primary isolates. However, these antibody specificities are rare, are not induced by Env immunization or HIV-1 infection, and are polyspecific and also react with lipids such as cardiolipin or phosphatidylserine. To probe MPER anti-gp41 antibodies that are produced in HIV-1 infection, we have made two novel murine MAbs, 5A9 and 13H11, against HIV-1 gp41 envelope that partially cross-blocked 2F5 MAb binding to Env but did not neutralize HIV-1 primary isolates or bind host lipids. Competitive inhibition assays using labeled 13H11 MAb and HIV-1-positive patient plasma samples demonstrated that cluster II 13H11-blocking plasma antibodies were made in 83% of chronically HIV-1 infected patients and were acquired between 5 to 10 weeks after acute HIV-1 infection. Both the mouse 13H11 MAb and the three prototypic cluster II human MAbs (98-6, 126-6, and 167-D) blocked 2F5 binding to gp41 epitopes to variable degrees; the combination of 98-6 and 13H11 completely blocked 2F5 binding. These data provide support for the hypothesis that in some patients, B cells make nonneutralizing cluster II antibodies that may mask or otherwise down-modulate B-cell responses to immunogenic regions of gp41 that could be recognized by B cells capable of producing antibodies like 2F5.
AbstractList	Two human monoclonal antibodies (MAbs) (2F5 and 4E10) against the human immunodeficiency virus type 1 (HIV-1) envelope g41 cluster II membrane proximal external region (MPER) broadly neutralize HIV-1 primary isolates. However, these antibody specificities are rare, are not induced by Env immunization or HIV-1 infection, and are polyspecific and also react with lipids such as cardiolipin or phosphatidylserine. To probe MPER anti-gp41 antibodies that are produced in HIV-1 infection, we have made two novel murine MAbs, 5A9 and 13H11, against HIV-1 gp41 envelope that partially cross-blocked 2F5 MAb binding to Env but did not neutralize HIV-1 primary isolates or bind host lipids. Competitive inhibition assays using labeled 13H11 MAb and HIV-1-positive patient plasma samples demonstrated that cluster II 13H11-blocking plasma antibodies were made in 83% of chronically HIV-1 infected patients and were acquired between 5 to 10 weeks after acute HIV-1 infection. Both the mouse 13H11 MAb and the three prototypic cluster II human MAbs (98-6, 126-6, and 167-D) blocked 2F5 binding to gp41 epitopes to variable degrees; the combination of 98-6 and 13H11 completely blocked 2F5 binding. These data provide support for the hypothesis that in some patients, B cells make nonneutralizing cluster II antibodies that may mask or otherwise down-modulate B-cell responses to immunogenic regions of gp41 that could be recognized by B cells capable of producing antibodies like 2F5. Two human monoclonal antibodies (MAbs) (2F5 and 4E10) against the human immunodeficiency virus type 1 (HIV-1) envelope g41 cluster II membrane proximal external region (MPER) broadly neutralize HIV-1 primary isolates. However, these antibody specificities are rare, are not induced by Env immunization or HIV-1 infection, and are polyspecific and also react with lipids such as cardiolipin or phosphatidylserine. To probe MPER anti-gp41 antibodies that are produced in HIV-1 infection, we have made two novel murine MAbs, 5A9 and 13H11, against HIV-1 gp41 envelope that partially cross-blocked 2F5 MAb binding to Env but did not neutralize HIV-1 primary isolates or bind host lipids. Competitive inhibition assays using labeled 13H11 MAb and HIV-1-positive patient plasma samples demonstrated that cluster II 13H11-blocking plasma antibodies were made in 83% of chronically HIV-1 infected patients and were acquired between 5 to 10 weeks after acute HIV-1 infection. Both the mouse 13H11 MAb and the three prototypic cluster II human MAbs (98-6, 126-6, and 167-D) blocked 2F5 binding to gp41 epitopes to variable degrees; the combination of 98-6 and 13H11 completely blocked 2F5 binding. These data provide support for the hypothesis that in some patients, B cells make nonneutralizing cluster II antibodies that may mask or otherwise down-modulate B-cell responses to immunogenic regions of gp41 that could be recognized by B cells capable of producing antibodies like 2F5.Two human monoclonal antibodies (MAbs) (2F5 and 4E10) against the human immunodeficiency virus type 1 (HIV-1) envelope g41 cluster II membrane proximal external region (MPER) broadly neutralize HIV-1 primary isolates. However, these antibody specificities are rare, are not induced by Env immunization or HIV-1 infection, and are polyspecific and also react with lipids such as cardiolipin or phosphatidylserine. To probe MPER anti-gp41 antibodies that are produced in HIV-1 infection, we have made two novel murine MAbs, 5A9 and 13H11, against HIV-1 gp41 envelope that partially cross-blocked 2F5 MAb binding to Env but did not neutralize HIV-1 primary isolates or bind host lipids. Competitive inhibition assays using labeled 13H11 MAb and HIV-1-positive patient plasma samples demonstrated that cluster II 13H11-blocking plasma antibodies were made in 83% of chronically HIV-1 infected patients and were acquired between 5 to 10 weeks after acute HIV-1 infection. Both the mouse 13H11 MAb and the three prototypic cluster II human MAbs (98-6, 126-6, and 167-D) blocked 2F5 binding to gp41 epitopes to variable degrees; the combination of 98-6 and 13H11 completely blocked 2F5 binding. These data provide support for the hypothesis that in some patients, B cells make nonneutralizing cluster II antibodies that may mask or otherwise down-modulate B-cell responses to immunogenic regions of gp41 that could be recognized by B cells capable of producing antibodies like 2F5.
Author	Plonk, Kelly Plonk, Steven G Haynes, Barton F Hicks, Charles B Sutherland, Laura L Scearce, Richard M Xia, Shi-Mao Karim, Salim Abdool Shaw, George M Zolla-Pazner, Susan Gorny, Miroslaw K Alam, S Munir Parks, Robert J Moody, M Anthony Tomaras, Georgia D Vanleeuwen, Stacie Montefiori, David C Liao, Hua-Xin Weinhold, Kent J Robinson, James
Author_xml	– sequence: 1 givenname: S Munir surname: Alam fullname: Alam, S Munir email: alam0004@mc.duke.edu organization: Human Vaccine Institute, Box 3258, Duke University Medical Center, MSRBII Bldg., Room 4042, Durham, NC 27710, USA. alam0004@mc.duke.edu – sequence: 2 givenname: Richard M surname: Scearce fullname: Scearce, Richard M – sequence: 3 givenname: Robert J surname: Parks fullname: Parks, Robert J – sequence: 4 givenname: Kelly surname: Plonk fullname: Plonk, Kelly – sequence: 5 givenname: Steven G surname: Plonk fullname: Plonk, Steven G – sequence: 6 givenname: Laura L surname: Sutherland fullname: Sutherland, Laura L – sequence: 7 givenname: Miroslaw K surname: Gorny fullname: Gorny, Miroslaw K – sequence: 8 givenname: Susan surname: Zolla-Pazner fullname: Zolla-Pazner, Susan – sequence: 9 givenname: Stacie surname: Vanleeuwen fullname: Vanleeuwen, Stacie – sequence: 10 givenname: M Anthony surname: Moody fullname: Moody, M Anthony – sequence: 11 givenname: Shi-Mao surname: Xia fullname: Xia, Shi-Mao – sequence: 12 givenname: David C surname: Montefiori fullname: Montefiori, David C – sequence: 13 givenname: Georgia D surname: Tomaras fullname: Tomaras, Georgia D – sequence: 14 givenname: Kent J surname: Weinhold fullname: Weinhold, Kent J – sequence: 15 givenname: Salim Abdool surname: Karim fullname: Karim, Salim Abdool – sequence: 16 givenname: Charles B surname: Hicks fullname: Hicks, Charles B – sequence: 17 givenname: Hua-Xin surname: Liao fullname: Liao, Hua-Xin – sequence: 18 givenname: James surname: Robinson fullname: Robinson, James – sequence: 19 givenname: George M surname: Shaw fullname: Shaw, George M – sequence: 20 givenname: Barton F surname: Haynes fullname: Haynes, Barton F
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/17942537$$D View this record in MEDLINE/PubMed
BookMark	eNpNkDlPxDAQhS0E4u6okSsqAnbirBM6hDiFRAO0Kx_jxRDbIbYR-8f4fZhLoprRm-89ad4WWvXBA0J7lBxRWnfHN4_XR4T0Na8IX0GblPRd1baUrf7bN9BWjM-EUMZmbB1tUN6zum34Jvq4yk54bJ3LPmgwVlnwaonf7JQjTssRMMWLkVEsfLIyaAtFfhIJOxFfsAMnJ-EBj1N4t04MeIKFDR7DaFMYIZ78-ZZYWq-tX-AX6yFZFQ9xEbJKBT8slMZjSFDgEmLC9BWUB_F1LRwWKicoi4Fvww5aM2KIsPs7t9HDxfn92VV1e3d5fXZ6Wyk261LV19JQQ3sjZsZw2bJeE6hVr1olG942qlG0Fq1mzaxrNBAjZcc56EJxLhtTb6ODn9zy32uGmObORgXDUH4OOc55aZ70bVPA_V8wSwd6Pk6ljWk5_2u6_gSIwIbw
CitedBy_id	crossref_primary_10_1016_j_virol_2016_01_002 crossref_primary_10_1097_COH_0b013e32835d08a9 crossref_primary_10_1371_journal_pone_0025797 crossref_primary_10_1128_JVI_01955_16 crossref_primary_10_4049_jimmunol_1900069 crossref_primary_10_1371_journal_pone_0096790 crossref_primary_10_1371_journal_pone_0023532 crossref_primary_10_1089_aid_2010_0265 crossref_primary_10_1016_j_jviromet_2009_02_014 crossref_primary_10_1146_annurev_immunol_030409_101256 crossref_primary_10_1073_pnas_1317855110 crossref_primary_10_1128_JVI_02631_08 crossref_primary_10_3390_cells13010033 crossref_primary_10_1073_pnas_1103869108 crossref_primary_10_1016_j_chom_2014_08_006 crossref_primary_10_1096_fj_08_113142 crossref_primary_10_3390_vaccines10020187 crossref_primary_10_1128_JVI_05680_11 crossref_primary_10_1128_JVI_01031_14 crossref_primary_10_1073_pnas_1309842111 crossref_primary_10_1089_aid_2008_0213 crossref_primary_10_1128_JVI_01564_15 crossref_primary_10_1371_journal_pone_0007215 crossref_primary_10_1128_JVI_00426_12 crossref_primary_10_1016_j_vaccine_2009_05_059 crossref_primary_10_1038_nature12053 crossref_primary_10_1007_s00251_015_0890_x crossref_primary_10_1111_1348_0421_12045 crossref_primary_10_1186_1742_4690_11_44 crossref_primary_10_1371_journal_ppat_1003202 crossref_primary_10_1128_JVI_01680_10 crossref_primary_10_1186_1742_4690_7_54 crossref_primary_10_1073_pnas_0901474106 crossref_primary_10_1038_nature12893 crossref_primary_10_1016_j_virol_2009_05_015 crossref_primary_10_1073_pnas_1301456110 crossref_primary_10_1128_JVI_05601_11 crossref_primary_10_1016_j_virol_2009_07_041 crossref_primary_10_1128_JVI_00563_11 crossref_primary_10_1016_j_virol_2015_09_010 crossref_primary_10_1073_pnas_0912381107 crossref_primary_10_1128_JVI_00412_15 crossref_primary_10_1002_eji_201242974 crossref_primary_10_1084_jem_20110363 crossref_primary_10_1084_jem_20121977 crossref_primary_10_1128_JVI_06359_11 crossref_primary_10_4049_jimmunol_1302829 crossref_primary_10_1084_jem_20091281 crossref_primary_10_1186_1471_2172_12_33 crossref_primary_10_1038_nri2674 crossref_primary_10_1016_j_jaci_2008_03_036 crossref_primary_10_4049_jimmunol_0903346 crossref_primary_10_1371_journal_pone_0173577 crossref_primary_10_1038_mt_2016_123 crossref_primary_10_1074_jbc_M114_569566 crossref_primary_10_1007_s11904_019_00432_x crossref_primary_10_1016_j_virol_2012_05_005 crossref_primary_10_1371_journal_ppat_1003431 crossref_primary_10_1002_jmr_1004 crossref_primary_10_1371_journal_pone_0027824 crossref_primary_10_1073_pnas_2026752118 crossref_primary_10_3389_fimmu_2021_613045 crossref_primary_10_3389_fimmu_2017_01154 crossref_primary_10_1126_scitranslmed_3007730 crossref_primary_10_1128_JVI_00305_08 crossref_primary_10_1016_j_chom_2014_07_003 crossref_primary_10_1128_JVI_01887_13 crossref_primary_10_1038_mi_2011_21 crossref_primary_10_1016_j_immuni_2012_11_011 crossref_primary_10_1128_JVI_00718_12 crossref_primary_10_1097_QAD_0b013e32834507bd crossref_primary_10_1128_JVI_01708_08 crossref_primary_10_1021_jacs_8b10848 crossref_primary_10_1128_CVI_00615_12 crossref_primary_10_1111_imr_12508 crossref_primary_10_1016_j_bios_2011_11_008 crossref_primary_10_1038_mi_2015_70 crossref_primary_10_1371_journal_pone_0101863 crossref_primary_10_1097_COH_0b013e32832f129e crossref_primary_10_1159_000438484 crossref_primary_10_1116_1_3432480 crossref_primary_10_1038_nsmb_1944 crossref_primary_10_1128_MMBR_00020_07 crossref_primary_10_1002_cbic_200800609 crossref_primary_10_4049_jimmunol_1302511 crossref_primary_10_1111_imr_12072 crossref_primary_10_1371_journal_ppat_1005042 crossref_primary_10_1128_JVI_00156_14 crossref_primary_10_4049_jimmunol_1300971
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1128/JVI.00927-07
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Biology
EISSN	1098-5514
ExternalDocumentID	17942537
Genre	Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NIAID NIH HHS grantid: U19 AI067854 – fundername: NIAID NIH HHS grantid: U19 AI051794 – fundername: NIAID NIH HHS grantid: U01 AI0678501 – fundername: NIAID NIH HHS grantid: U19AI51794 – fundername: NIAID NIH HHS grantid: AI27742 – fundername: NIAID NIH HHS grantid: U01 AI067854 – fundername: NIAID NIH HHS grantid: T32 AI007392 – fundername: NIAID NIH HHS grantid: AI40237 – fundername: NIAID NIH HHS grantid: P30 AI027742
GroupedDBID	--- -~X .55 .GJ 0R~ 18M 29L 2WC 39C 3O- 4.4 41~ 53G 5GY 5RE 5VS 6TJ 85S AAFWJ AAGFI AAYJJ ABPPZ ACGFO ACNCT ADBBV ADXHL AENEX AFFNX AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CGR CS3 CUY CVF D0S DIK E3Z EBS ECM EIF EJD F5P FRP GX1 H13 HYE HZ~ IH2 KQ8 MVM N9A NPM O9- OHT OK1 P2P RHI RNS RPM RSF TR2 UPT VH1 W2D W8F WH7 WOQ X7M Y6R YQT ZGI ZXP ~02 ~KM 7X8
ID	FETCH-LOGICAL-c468t-92bf1f19fa6ff7b549d0e2c9c5cb3753c3c12a5d43683de0fbb877edd0e77b3f2
IEDL.DBID	7X8
ISICitedReferencesCount	107
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000251838600011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1098-5514
IngestDate	Thu Oct 02 05:59:50 EDT 2025 Mon Jul 21 06:03:30 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c468t-92bf1f19fa6ff7b549d0e2c9c5cb3753c3c12a5d43683de0fbb877edd0e77b3f2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
OpenAccessLink	http://doi.org/10.1128/JVI.00927-07
PMID	17942537
PQID	70090953
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_70090953 pubmed_primary_17942537
PublicationCentury	2000
PublicationDate	2008-01-01
PublicationDateYYYYMMDD	2008-01-01
PublicationDate_xml	– month: 01 year: 2008 text: 2008-01-01 day: 01
PublicationDecade	2000
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Journal of virology
PublicationTitleAlternate	J Virol
PublicationYear	2008
References	14557656 - J Virol. 2003 Nov;77(21):11708-17 12594946 - Immunity. 2003 Feb;18(2):185-92 12644702 - Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9 7520721 - AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69 12478295 - Nature. 2002 Dec 12;420(6916):678-82 1689663 - Eur J Immunol. 1990 Jan;20(1):229-32 1714520 - J Virol. 1991 Sep;65(9):4832-8 2856526 - Transfus Med Rev. 1988 Sep;2(3):129-50 12641452 - Biochemistry. 2003 Mar 25;42(11):3214-23 16904645 - Biochem Biophys Res Commun. 2006 Sep 29;348(3):1107-15 11602730 - J Virol. 2001 Nov;75(22):10906-11 15793563 - Nature. 2005 Apr 28;434(7037):1093-7 9095159 - Nat Med. 1997 Apr;3(4):366-7 16971434 - J Virol. 2006 Dec;80(23):11776-90 2986291 - Science. 1985 May 31;228(4703):1094-6 16474158 - J Virol. 2006 Mar;80(5):2515-28 12443671 - Vaccine. 2002 Nov 22;21(1-2):127-37 12719582 - J Virol. 2003 May;77(10):5889-901 9545219 - Science. 1998 Apr 17;280(5362):427-31 17151131 - J Virol. 2007 Feb;81(4):2087-91 17067270 - AIDS Res Hum Retroviruses. 2006 Oct;22(10):998-1006 15078183 - Curr HIV Res. 2004 Apr;2(2):193-204 14021558 - Br Med J. 1963 Apr 13;1(5336):979-84 15099755 - J Immunol Methods. 2004 Apr;287(1-2):49-65 1704000 - Intervirology. 1990;31(6):327-38 15367639 - J Virol. 2004 Oct;78(19):10724-37 11602729 - J Virol. 2001 Nov;75(22):10892-905 17055621 - Vaccine. 2007 Jun 28;25(27):5102-14 16720975 - Hum Antibodies. 2005;14(3-4):59-67 16989613 - AIDS Res Hum Retroviruses. 2006 Sep;22(9):874-83 1700004 - J Immunol. 1990 Nov 15;145(10):3276-82 14697742 - Clin Immunol. 2003 Dec;109(3):278-87 10612661 - Virology. 2000 Jan 5;266(1):66-78 17409164 - J Virol. 2007 Jun;81(12):6187-96 12646921 - Nature. 2003 Mar 20;422(6929):307-12 11560957 - J Clin Invest. 2001 Sep;108(6):879-86 11788027 - AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1757-65 17039602 - Virology. 2006 Sep 30;353(2):268-82 10846104 - J Virol. 2000 Jul;74(13):6186-92 15365095 - J Exp Med. 2004 Sep 20;200(6):761-70 11884575 - J Virol. 2002 Apr;76(7):3511-21 9200464 - J Immunol. 1997 Jul 1;159(1):279-89 2455899 - Proc Natl Acad Sci U S A. 1988 Jul;85(14):5225-9 15723805 - Immunity. 2005 Feb;22(2):163-73 15320988 - AIDS Res Hum Retroviruses. 2004 Aug;20(8):836-45 6631009 - J Immunol. 1983 Nov;131(5):2196-203 7888224 - AIDS Res Hum Retroviruses. 1994 Dec;10(12):1651-8 17372000 - J Immunol. 2007 Apr 1;178(7):4424-35 15365096 - J Exp Med. 2004 Sep 20;200(6):749-59 1701315 - AIDS Res Hum Retroviruses. 1990 Oct;6(10):1183-92 16219699 - Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):14943-8 15860590 - Science. 2005 Jun 24;308(5730):1906-8 16827619 - Expert Rev Vaccines. 2006 Jun;5(3):347-63 10984542 - Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10532-7 16918684 - Scand J Immunol. 2006 Sep;64(3):177-84 8744581 - AIDS Res Hum Retroviruses. 1996 May 20;12(8):705-13
References_xml	– reference: 1689663 - Eur J Immunol. 1990 Jan;20(1):229-32 – reference: 15320988 - AIDS Res Hum Retroviruses. 2004 Aug;20(8):836-45 – reference: 10612661 - Virology. 2000 Jan 5;266(1):66-78 – reference: 2986291 - Science. 1985 May 31;228(4703):1094-6 – reference: 15365096 - J Exp Med. 2004 Sep 20;200(6):749-59 – reference: 8744581 - AIDS Res Hum Retroviruses. 1996 May 20;12(8):705-13 – reference: 15099755 - J Immunol Methods. 2004 Apr;287(1-2):49-65 – reference: 11602729 - J Virol. 2001 Nov;75(22):10892-905 – reference: 16918684 - Scand J Immunol. 2006 Sep;64(3):177-84 – reference: 2455899 - Proc Natl Acad Sci U S A. 1988 Jul;85(14):5225-9 – reference: 16474158 - J Virol. 2006 Mar;80(5):2515-28 – reference: 16720975 - Hum Antibodies. 2005;14(3-4):59-67 – reference: 11884575 - J Virol. 2002 Apr;76(7):3511-21 – reference: 2856526 - Transfus Med Rev. 1988 Sep;2(3):129-50 – reference: 12719582 - J Virol. 2003 May;77(10):5889-901 – reference: 12443671 - Vaccine. 2002 Nov 22;21(1-2):127-37 – reference: 11788027 - AIDS Res Hum Retroviruses. 2001 Dec 10;17(18):1757-65 – reference: 11560957 - J Clin Invest. 2001 Sep;108(6):879-86 – reference: 15793563 - Nature. 2005 Apr 28;434(7037):1093-7 – reference: 1701315 - AIDS Res Hum Retroviruses. 1990 Oct;6(10):1183-92 – reference: 10846104 - J Virol. 2000 Jul;74(13):6186-92 – reference: 17372000 - J Immunol. 2007 Apr 1;178(7):4424-35 – reference: 6631009 - J Immunol. 1983 Nov;131(5):2196-203 – reference: 17055621 - Vaccine. 2007 Jun 28;25(27):5102-14 – reference: 15367639 - J Virol. 2004 Oct;78(19):10724-37 – reference: 1704000 - Intervirology. 1990;31(6):327-38 – reference: 1700004 - J Immunol. 1990 Nov 15;145(10):3276-82 – reference: 16219699 - Proc Natl Acad Sci U S A. 2005 Oct 18;102(42):14943-8 – reference: 11602730 - J Virol. 2001 Nov;75(22):10906-11 – reference: 7888224 - AIDS Res Hum Retroviruses. 1994 Dec;10(12):1651-8 – reference: 17067270 - AIDS Res Hum Retroviruses. 2006 Oct;22(10):998-1006 – reference: 10984542 - Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10532-7 – reference: 15078183 - Curr HIV Res. 2004 Apr;2(2):193-204 – reference: 16971434 - J Virol. 2006 Dec;80(23):11776-90 – reference: 7520721 - AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69 – reference: 16904645 - Biochem Biophys Res Commun. 2006 Sep 29;348(3):1107-15 – reference: 17151131 - J Virol. 2007 Feb;81(4):2087-91 – reference: 12644702 - Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9 – reference: 1714520 - J Virol. 1991 Sep;65(9):4832-8 – reference: 17409164 - J Virol. 2007 Jun;81(12):6187-96 – reference: 12641452 - Biochemistry. 2003 Mar 25;42(11):3214-23 – reference: 12646921 - Nature. 2003 Mar 20;422(6929):307-12 – reference: 9545219 - Science. 1998 Apr 17;280(5362):427-31 – reference: 17039602 - Virology. 2006 Sep 30;353(2):268-82 – reference: 14021558 - Br Med J. 1963 Apr 13;1(5336):979-84 – reference: 12594946 - Immunity. 2003 Feb;18(2):185-92 – reference: 9095159 - Nat Med. 1997 Apr;3(4):366-7 – reference: 15860590 - Science. 2005 Jun 24;308(5730):1906-8 – reference: 16989613 - AIDS Res Hum Retroviruses. 2006 Sep;22(9):874-83 – reference: 12478295 - Nature. 2002 Dec 12;420(6916):678-82 – reference: 16827619 - Expert Rev Vaccines. 2006 Jun;5(3):347-63 – reference: 14557656 - J Virol. 2003 Nov;77(21):11708-17 – reference: 9200464 - J Immunol. 1997 Jul 1;159(1):279-89 – reference: 15723805 - Immunity. 2005 Feb;22(2):163-73 – reference: 14697742 - Clin Immunol. 2003 Dec;109(3):278-87 – reference: 15365095 - J Exp Med. 2004 Sep 20;200(6):761-70
SSID	ssj0014464
Score	2.2596464
Snippet	Two human monoclonal antibodies (MAbs) (2F5 and 4E10) against the human immunodeficiency virus type 1 (HIV-1) envelope g41 cluster II membrane proximal...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	115
SubjectTerms	Animals Antibodies, Monoclonal - immunology Antibodies, Monoclonal - isolation & purification Cross Reactions Epitopes - immunology HIV Antibodies - blood HIV Antibodies - immunology HIV Antibodies - metabolism HIV Envelope Protein gp41 - immunology HIV Infections - immunology HIV-1 - immunology Humans Kinetics Lipids - immunology Mice Neutralization Tests Protein Binding
Title	Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection
URI	https://www.ncbi.nlm.nih.gov/pubmed/17942537 https://www.proquest.com/docview/70090953
Volume	82
WOSCitedRecordID	wos000251838600011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LT9wwELYotFIvUAotlNccOBLIY7N2KiSEKlBBYsUB0N5WfoxphDYJJIvEH-vv60yyESfEoZccItuJPM5kHt98I8S-NtIOVYqBSxIXDIxVgTZWB0prNKHKQkxN22xCjkZqPM6uF8RxXwvDsMpeJ7aK2pWWY-RHkowB5kY7qR4D7hnFudV5A40PYikhQ4YBXXL8mkMgR6fNKTNjJtsFPew9VkeXdxeHzDbEUbq3Tcv2F3O-8n8v90Usz01LOO3OwqpYwOKr-NQ1m3xZE3_beD3kXBBSOmTmCC67hOf8aVYDh2IhgvtqEAFtdm5KhhdC80c3MNX1A0xxSo51gcDAl3xKD-KeDmUBWJFSqLD-2c97AZO3tTLwQCYs00AfAN3oaGoPaJSDqmwYpUSLkM3MC82biNE40HbWIPQgsWJd3J6f3fz6Hcy7NgR2MFRNkMXGRz7KvB56Lw35ny7E2GY2tSYh58gmNop16pj6PnEYemOUlOholJQm8fE3sViUBW4IyJAcHvShV0i6RsssNZkZ2lhZ59N4oDfFXi-OCX0VnOqgfShn9aQXyKb43kl0UnXkHRNWQHGayB_vzt0SnztwCMdbtsWSJ32AO-KjfW7y-mm3PWx0HV1f_QMY7OXI
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Human+immunodeficiency+virus+type+1+gp41+antibodies+that+mask+membrane+proximal+region+epitopes%3A+antibody+binding+kinetics%2C+induction%2C+and+potential+for+regulation+in+acute+infection&rft.jtitle=Journal+of+virology&rft.au=Alam%2C+S+Munir&rft.au=Scearce%2C+Richard+M&rft.au=Parks%2C+Robert+J&rft.au=Plonk%2C+Kelly&rft.date=2008-01-01&rft.issn=1098-5514&rft.eissn=1098-5514&rft.volume=82&rft.issue=1&rft.spage=115&rft_id=info:doi/10.1128%2FJVI.00927-07&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-5514&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-5514&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-5514&client=summon